Immunotherapy Continues to Impress in GU Malignancies – OncLive
OncLive |
Immunotherapy Continues to Impress in GU Malignancies
OncLive Single-agent immunotherapy continues to demonstrate durable responses in patients with urothelial carcinoma, and now, combination regimens are showing efficacy in both urothelial carcinoma and rarer genitourinary (GU) tumors. In a phase I study, the … |
